Cerebral Toxoplasmosis and AIDS (TOXODFA)
|ClinicalTrials.gov Identifier: NCT00803621|
Recruitment Status : Completed
First Posted : December 5, 2008
Last Update Posted : March 26, 2014
With a HIV incidence much higher in the DFA than in European French territory, this disease is a major public health problem in these areas, especially in French Guiana.
Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from the DFA because of its frequency (French West Indies) and of its lethality (French Guiana).
The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. The response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis.
In reference to the data collected by the Biological Resource Centre Toxoplasma, in particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients from DFA are genetically different from those reactivating in AIDS patients from Europe, with an increased capacity for dissemination via peripheral blood in the first ones. This more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French departments of America.
|Condition or disease||Intervention/treatment|
|Cerebral Toxoplasmosis AIDS||Other: Toxoplasma PCR assay|
|Study Type :||Observational|
|Actual Enrollment :||46 participants|
|Official Title:||Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2013|
Other: Toxoplasma PCR assay
- Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA. [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00803621
|Service des Maladies Infectieuses - CHU de Pointe à Pitre|
|Pointe à Pitre, Guadeloupe, France|
|Services Maladies Infectieuses et Tropicales- CHU Fort-de-France|
|Dermatologie et CISIH- CH Andrée Rosemon|
|Maladies Infectieuses et Tropicales - CH Andrée Rosemon|
|Médecine- CH Ouest Guyanais|
|Study Director:||Daniel AJZENBERG, PharmD, PhD||CHU Limoges|